Endocrine Abstracts

IntroductionOsilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during the 48-week (W) core phase of a Phase III study (LINC3: NCT02180217). We present efficacy and safety results following an extension to LINC3.MethodsCD patients with mUFC > 1.5× upper limit of normal (ULN) received osilodrostat during the core. Patients b...

During the spring of 2020, a national lockdown was adopted in Italy to prevent COVID-19 pandemic spread. Restrictive measures have been associated with impaired psychological outcome in the general population. As patients with Cushing’s Syndrome (CS), including Cushing’s disease (CD), adrenal CS (ACS), and ectopic CS (ECS), are reportedly associated with a higher prevalence of anxiety, stress susceptibility, depression, and maniac episodes, during both active disease...

Background: Since the preliminary epidemiological data concerning the coronavirus disease 2019 (COVID-19) has been availabe, clear sex disparity has been evident, with males, although not more frequently affected, often experiencing worse outcomes when compared to women. The short and long term andrological effects of coronavirus disease 2019 (COVID-19) have not been clarified. The aim of the present study is to systematically review and meta-analyze all available data regardi...

State of the art: In pharmacology, human chorionic gonadotropin (hCG) is considered equivalent to luteinising hormone (LH) since both act on the same receptor. Thus, when testicular function needs to be clinically restored (i.e. in case of hypogonadotropic hypogonadism [HH]), hCG is used instead of LH. However, growing evidences showed LH and hCG activate different molecular pathways and offer different outcomes in women undergoing assisted reproduction. The different action b...

In patients with Cushing syndrome (CS), hypercoagulability represents a significant concern, leading to elevated risk for thrombotic events. After curative surgery, hypercoagulability persists for several months; CS treatment guidelines recommend anticoagulation therapy for ≤ 3 months. In patients with Cushing disease, hemostatic parameters may even worsen after surgery, independent of surgical outcome; improvements begin ~3 months after successful surgery (Casonato ...

Introduction: Osilodrostat (oral 11β-hydroxylase inhibitor) demonstrated rapid, sustained cortisol normalisation in Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734) in patients with Cushing’s disease (CD). Relative osilodrostat bioavailability is ~20% higher in Asian patients than other ethnicities; body weight is not a major determinant of this difference. This analysis of LINC 3 and LINC 4 evaluated osilodrostat efficacy and safety in Asian and non-Asia...

Background and objective: Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding practical management of mitotane treatment and its eventual combination with chemotherapy or radiotherapy. The aim of the study is to do a survey on the use of mitotane for advanced ACC in expert Italian centers, analyzing data of the LYSOSAFE database.Methods: Retrospective analysis of patients ...

A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 15–28% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...

Introduction: During the 22-week LINC-2 study, the potent oral 11β-hydroxylase inhibitor osilodrostat normalized UFC in 15/19 (78.9%) patients with Cushing’s disease. Most common AEs were nausea, diarrhoea, asthenia, and adrenal insufficiency. This report describes 19-month results following an extension.Methods: Patients who were receiving clinical benefit at week 22 could enter the extension. Efficacy/safety is reported for patients who enter...

The mTOR and IGF pathways have been suggested to play a role in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus (S) and everolimus (E), as well as IGF1R antagonists could be a potential novel treatment for malignant PPC.The aim of this study was to evaluate the expression of the main components of the IGF/mTOR pathway in human PCC and to investigate the effects of the mTOR inhibitors S and E and of the IGF1R/insulin receptor (I...